Preclinical studies of group A streptococcal vaccine candidates

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1000512

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Development Grants

Funding Amount: $532,492.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Bacteriology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Streptococcus pyogenes | streptococcal disease | vaccine-preventable diseases | vaccines

Related Links